BackOncotelic Therapeutics Overview
Oncotelic Therapeutics, Inc.

Oncotelic Therapeutics Return on Equity

Latest ROE for Oncotelic Therapeutics: 93.55% — see history and peer comparisons.

Get informed when a big investor buys or sells

+ Follow

ROE

93.55%

Return on Equity

93.55%

Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.

ROE (Comparison Companies)

Loading

ROE History

Loading

ROE Comparison

Loading

Oncotelic Therapeutics (OTLC) FAQ

As of the most recent data, OTLC shows a ROE of 93.55%. That is above the Healthcare sector average of 13.1%. Scroll down for historical charts and peer comparison views.

The Healthcare sector average ROE is about 13.1%. Oncotelic Therapeutics is at 93.55%, which is higher that average. That is roughly 613.9% above the sector mean. Use the comparison chart on this page to see how OTLC stacks up against individual peers as well.

Check the historical chart to see whether OTLC's ROE is trending up or down. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare Oncotelic Therapeutics with peers to see if the move is company-specific or sector-wide.

Besides this return on equity page, Stockcircle has Oncotelic Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect ROE (currently 93.55%) with ownership activity and broader fundamentals.

The Healthcare average ROE is about 13.1%, while OTLC is at 93.55%. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.